Recently, a monoclonal MuSK antibody was shown to stimulate MuSK phosphorylation and to preserve NMJs in a motor neuron disease model.23 Using new or repurposed drugs to enhance MuSK phosphorylation, or other downstream components of the signaling pathway, could be beneficial in MuSK-Ab myasthenia and perhaps in other disorders of neuromuscular transmission where loss of AChRs or disruption of the NMJ structure underlies the muscle weakness. This evidence concerns the gene MUSK and motor neuron disorder.